IL10 and COVID-19: Taken together, these evidence have robustly supported the great potentiality of monitoring circulating levels of IL-10 in COVID-19 patients as reliable biomarker to rapidly predict the disease course at the first stages of infection, to early recognize patients with higher risk of developing detrimental complications (231) and to accurately determine the most suitable therapeutic options and the right time of treatment administration (228, 234).